RxDoctor Payments DataLook up a doctor →

Arby Cohen, NP

Nurse Practitioner · Houston, TXNPI 1871118570

Payments from drug & device makers

$23,146in general payments, 2019–2025

Across 709 payments — averaging $32.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$3K
  • Johnson & Johnson$2K
  • AstraZeneca$1K
  • Merck$1K
  • Novartis$968
  • Seagen Inc.$753
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$1,3006%
  • Travel & lodging$9024%
  • Food & beverage$19,79986%
  • Education$1,1465%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sobi, Inc15$2,607
Johnson & Johnson(2 entities)40$1,741
AstraZeneca(2 entities)50$1,438
Merck43$1,103
Novartis50$968
Seagen Inc.14$753
E.r. Squibb & Sons, L.L.C.27$740
Daiichi Sankyo Inc.29$734
Pfizer27$650
GSK14$643
Exelixis Inc.40$631
Lilly USA, LLC22$623
Rigel Pharmaceuticals, Inc.20$619
Incyte Corporation22$609
Eisai Inc.14$604
Bristol Myers Squibb25$580
Bayer16$498
Sanofi17$486
Astellas Pharma US Inc13$486
Gilead(2 entities)10$448
Beigene USA, Inc.6$426
Amgen16$412
AbbVie9$378
Genentech USA, Inc.14$323
Morphosys, US Inc.14$289
AVEO Pharmaceuticals, Inc.11$272
Myriad Genetic Laboratories, Inc.3$253
Janssen Scientific Affairs, LLC2$222
Boston Scientific8$219
Takeda Pharmaceuticals U.S.A., Inc.9$212
Regeneron Healthcare Solutions, Inc.8$210
Epizyme, Inc.2$201
Stemline Therapeutics Inc.4$196
Pharmacyclics LLC, An Abbvie Company7$192
Pharmacosmos Therapeutics Inc.3$180
Springworks Therapeutics, Inc.9$154
Taiho Oncology, Inc.7$151
Myovant Sciences Inc.5$134
CTI Biopharma Corp.6$129
ADC Therapeutics America, Inc.1$122
Veracyte, Inc.1$115
Heron Therapeutics, Inc.1$111
Kyowa Kirin, Inc.5$107
Array Biopharma Inc4$102
BTG International Inc.1$97
Servier Pharmaceuticals LLC5$96
Agios Pharmaceuticals, Inc.1$84
Deciphera Pharmaceuticals Inc.3$80
Puma Biotechnology, Inc.3$77
EMD Serono, Inc.4$72
G1 Therapeutics, Inc.3$68
Sumitomo Pharma America, Inc.3$65
Apellis Pharmaceuticals, Inc.3$58
Mirati Therapeutics, Inc.3$53
Ipsen Biopharmaceuticals, Inc3$52
Karyopharm Therapeutics Inc.3$51
Adaptive Biotechnologies Corporation2$47
Pharmaessentia USA Corporation2$43
Genmab U.S., Inc.2$39
Sirtex Medical Inc1$30

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,146 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$7,393
Medicare patients
56
Services billed
91

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban19$19,010
Famciclovir13$815
Anastrozole20$373
LoperamideLoperamide Hcl25$305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$650$19,01019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →